iiinova — where your digital self keeps evolving

UCL Business @uclb.bsky.social · 25/11/2025

4/ of AUCATZYL® by the UK MHRA earlier this year. It has also been approved for use in eligible patients in the U.S and in the EU. Congratulations to the whole Autolus team on this important obe-cel milestone that will change people’s lives. Learn more here: www.uclb.com/2025/11/25/n...

uclb.com

Breakthrough immunotherapy treatment for leukaemia to be made available to NHS patients

NICE has announced that AUCATZYL® can be made available on the NHS to eligible patients with acute lymphoblastic leukaemia.

010

UCL Business @uclb.bsky.social · 25/11/2025

3/ the specific signature of their cancer. These cells are then returned to the body as ‘living medicine’. Crucially, obe-cel is a major improvement on existing CAR T technology, which remains active in the body over longer periods and causes fewer side effects. The NICE decision follows approval

110

UCL Business @uclb.bsky.social · 25/11/2025

2/ to NHS patients ‘within weeks’. It can be used in adult patients with acute lymphoblastic leukaemia (ALL), which has not responded to treatment or has returned. AUCATZYL® is the product name for a variant of CAR T-cell therapy which reprogrammes a patient’s T-cells to recognise and target

100

UCL Business @uclb.bsky.social · 25/11/2025

NICE has today announced that AUCATZYL® can be made available on the NHS to eligible patients with acute lymphoblastic leukaemia! 🥳 This huge step forward means the pioneering immunotherapy treatment, developed by UCLB spinout venture Autolus Therapeutics, will be available 1/

110

UCL Business @uclb.bsky.social · 10/11/2025

... to the expert workshop on this guidance last week, discussing how to attract investment while protecting institutional interests and be financially sustainable. She shared more about the UK’s experience through the USIT Guide, our founder-friendly equity deals: our Portico Ventures 2/

110

UCL Business @uclb.bsky.social · 10/11/2025

Europe wants to lead the way for ease and fairness of IP commercialisation. Under the EU Startup and Scaleup Strategy, the European Commission is creating a blueprint for licensing, revenue-sharing, & equity participation for academic institutions & inventors. Our CEO, Anne Lane, contributed 1/

eu flags with the caption below: Anne Lane contributes to EU blueprint workshop for licensing and spinoff creation

120

UCL Business @uclb.bsky.social · 07/11/2025

... even AZ and Merck have chosen to retreat. The cutting-edge tech & life-changing research coming out of institutions like UCL could help realise the first homegrown trillion-pound company. There is plenty to be excited about - read the article here (p39): onenucleus.com/publications 2/

onenucleus.com

Publications | One Nucleus

010

UCL Business @uclb.bsky.social · 07/11/2025

The AI revolution in life sciences is already here – and it’s changing the sector. Our CEO, Anne Lane has written about university spinouts, AI and investment in the UK for One Nucleus, sharing her excitement for the potential of the sector here in Britain... 1/

120

UCL Business @uclb.bsky.social · 04/11/2025

Previously, he was focused on producing excellent academic research, but now - after licensing his own work - Stefan is keen to patent technologies and see them used in real-world applications, alongside writing high quality, impactful papers. See you at our next IO Converse in January? 2/

010

UCL Business @uclb.bsky.social · 04/11/2025

Thank you to Professor Stefan Howorka for his insightful contributions at our recent IO Converse session! Professor Howorka, a pioneer of nanopore technology, shared that his attitude towards research has shifted following his journey to commercialisation in a discussion with Barny Cox. 1/

110

UCL Business @uclb.bsky.social · 28/10/2025

... one that is already offering hope to blood cancer patients. Emily Henders, a 37-year-old biology teacher & mum of two, shared her decision to participate with Sky News. We look forward to seeing how this trial develops! 👏 Read more: www.uclb.com/2025/10/24/a... 3/

uclb.com

Autolus breaks new ground: first MS patient dosed in obe-cel Phase 1 trial

UCLB spinout Autolus Therapeutics has announced a major milestone: the first patient dosed in its Phase 1 BOBCAT trial of obecabtagene autoleucel (obe-cel) for progressive multiple sclerosis (PMS).

010

UCL Business @uclb.bsky.social · 28/10/2025

This ‘one-time’ treatment sees patients receive an infusion of their own T-cells, modified to recognise and hunt down rogue elements in their immune system, which are the underlying cause of multiple sclerosis. The beginning of the trial marks a significant expansion of the therapy platform... 2/

110

UCL Business @uclb.bsky.social · 28/10/2025

A groundbreaking multiple sclerosis trial, that could offer hope to millions, has begun using Autolus Therapeutics CAR T-cell therapy platform. Patients with progressive multiple sclerosis (PMS) are receiving 'obe-cel' treatment in this phase 1 trial at UCL Hospitals NHS Foundation Trust. 1/

Woman in hospital bed receives treatment from a nurse, while she talks to a doctor at the foot of her bed. Family members in the room look on hopefully

111

UCL Business @uclb.bsky.social · 21/10/2025

UCL and its spinouts are leaders for equity investment, according to the Beauhurst report! 🏆 The analytics company ranked UCL fourth for the number of equity deals secured by spinouts in 2024, and second for equity deal volume.

100

UCL Business @uclb.bsky.social · 17/10/2025

Ana said: > 𝗘𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲: evaluating ideas, shaping business plans, offering IP or licensing advice > 𝗡𝗲𝘁𝘄𝗼𝗿𝗸𝘀: connecting founders with advisers & collaborators > 𝗙𝗶𝗻𝗮𝗻𝗰𝗲: helping with grant applications, translational funding, providing PoC funds to test / prototype ideas and more were vital.

010

UCL Business @uclb.bsky.social · 17/10/2025

How can universities support founders of social ventures? 🤝 This was the topic of discussion at the Bates Wells and London Social Venture (LSV) event on 9th October... Analia Lemmo, UCLB Senior Business Manager, joined the panel to share how ideas can be turned into impact.

110

UCL Business @uclb.bsky.social · 30/09/2025

UCLB is proud to call the Euston Knowledge Quarter home and be leading the momentum with: - 95 active spinouts across healthcare, AI, and tech - Over £3 billion raised in external investment over the last five years - and the creation of 2,400 jobs.

010

UCL Business @uclb.bsky.social · 30/09/2025

The trajectory of this possibility is incredibly exciting: adding £3.5 billion to the economy, creating 30,000 new jobs, and driving breakthroughs in cancer, Alzheimer’s, sustainable energy & more. Such growth would exceed that of Boston's Kendall Sqaure...!

110

UCL Business @uclb.bsky.social · 30/09/2025

What if the next global innovation supercluster wasn’t in Boston or Silicon Valley - but in Euston? 🌍 Our CEO Anne Lane joined leaders from Camden Council, Lendlease, UCL partner hospitals and more for the 'Unlocking Inclusive Growth Through Innovation' breakfast at #Lab25 in Liverpool yesterday.

Woman in purple jacket with blonde hair talks enthusiastically, sat at a table with others over coffee.

120

UCL Business @uclb.bsky.social · 29/09/2025

... in introducing an innovative protein pore into ONT's devices. Dr Barny Cox, Senior Business Manager at UCLB, will chair the session on: 📅 16 October 2025 🕑 12.30pm-2pm (light lunch provided) 📍 90 Tottenham Court Road Register your place here: www.eventbrite.co.uk/e/io-convers... 2/

eventbrite.co.uk

IO Converse:

Revolutionising biotechnology through nanopore sequencing

010

UCL Business @uclb.bsky.social · 29/09/2025

🚨IO Converse is back! Don't miss your chance to hear from @ucl.ac.uk’s Professor Stefan Howorka about his journey from academic research to real-world impact. Prof. Howorka will discuss his experience working with Oxford Nanopore Technologies, an Oxford spinout, including his pivotal role... 1/

110

UCL Business @uclb.bsky.social · 23/09/2025

... of development of many of our highly successful spinouts across a multitude of disciplines. Take a look at our stats on PoC funding or find out more about how it's helped UCL spinouts: www.uclb.com/2025/09/23/t... 3/3

010

UCL Business @uclb.bsky.social · 23/09/2025

Both were nominated by UCLB. PoC funding has been a vital part of the commercialisation landscape at UCL for almost 20 years. It helps bridge the funding gap between research grants and investment, supporting the early stages... 2/3

110

UCL Business @uclb.bsky.social · 23/09/2025

Thrilled to announce two @ucl.ac.uk researchers have been awarded Proof of Concept funding by @ukri.org. Max Besenhard's smart chromatography for sustainable drug analysis and purification has been recognised, as has Youngjun Cho's accessible journey planner for disabled people, AI Mapper+. 1/3

110

UCL Business @uclb.bsky.social · 19/09/2025

The IO Inspire Autumn Programme begins next month! ⌛ IO Inspire is a free weekly lunchtime programme for UCL academics looking to explore the commercial potential of their research. Find out more and register for the programme here: www.eventbrite.co.uk/e/io-inspire...

010

Reposted by UCL Business

nickchodgson.bsky.social @nickchodgson.bsky.social · 16/09/2025

Good news! Google has said it will invest £5bn in the UK in the next two years to help meet growing demand for artificial intelligence services, in a boost for the government, @theguardian.com reports. Coincides with US president Donald Trump's visit @uclb.bsky.social @profgeraintrees.bsky.social

theguardian.com

Google announces £5bn AI investment in UK before Trump visit

Rachel Reeves says move is a ‘vote of confidence’ in British economy as she prepares to open firm’s first UK datacentre

131

Reposted by UCL Business

UCL News @uclnews.bsky.social · 14/09/2025

Could these companies be turning their backs at precisely the wrong moment?, asks @profgeraintrees.bsky.social after US firm Merck put the brakes on a £1 billion London research centre & AstraZeneca said it would pause a £200m investment to expand its research and development arm in Cambridge

thetimes.com

Why Merck and AstraZeneca may regret turning their back on Britain

The pair may have gone cold on the UK but start-ups and university spinouts here are using AI to revolutionise drug discovery

0179

UCL Business @uclb.bsky.social · 12/09/2025

This Stand Up To Cancer Day, we highlight the latest groundbreaking work in oncology by UCLB’s spinouts, licences and partnerships. You can read our Stand Up To Cancer Day news story here: www.uclb.com/2025/09/12/s...

010

Reposted by UCL Business

UCL Faculty of Brain Sciences @uclbrainscience.bsky.social · 08/09/2025

We're proud to be training the future leaders in dementia research! 🧠 💪 Read the story of Dr Daniel Andrés Jiménez, a @uclqsion.bsky.social MSc Dementia graduate who went on to advise the Chilean Ministry of Health on dementia: buff.ly/Ek6GbE8 #UCLDementia #WorldAlzheimersDay

Reads: “The Dementia course gave me a comprehensive view of dementia research at a crucial moment in my early research career. There are many research approaches and methods, and the course helped me understand which ones suited me best and how to kick off my career as a researcher.”

032

UCL Business @uclb.bsky.social · 05/09/2025

IO Inspire is a free weekly lunchtime programme for UCL academics looking to explore the commercial potential of their research. The Autumn intake will run from 𝟴𝘁𝗵 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 – 𝟯𝗿𝗱 𝗗𝗲𝗰𝗲𝗺𝗯𝗲𝗿. Find out more about the programme and how to register here: www.uclb.com/events/io-in...

010

UCL Business @uclb.bsky.social · 28/08/2025

A clinical trial conducted by UCL has shown for the first time how a commercially available gene expression test can accurately predict which patients with prostate cancer will benefit from chemotherapy with docetaxel. Find out about UCLB's involvement here: www.uclb.com/2025/08/28/g...

uclb.com

Gene test opens the possibility of personalised prostate cancer treatment

A clinical trial conducted by UCL has shown for the first time how a commercially available gene expression test can accurately predict which patients with prostate cancer that has spread will benefit...

030

UCL Business @uclb.bsky.social · 13/08/2025

Caitriona O'Rourke , Senior Business Manager, BioPharm, UCLB, shares her journey into science, beginning with a childhood fascination sparked by a microscope her father bought at a car boot sale. Read the full news story here: www.uclb.com/2025/08/13/e...

uclb.com

Early inspirations and exciting breakthroughs: a chat with UCLB’s Caitriona O'Rourke

Caitriona O’Rourke, Senior Business Manager, BioPharm, UCLB, shares her journey into science, beginning with a childhood fascination sparked by a microscope her father bought at a car boot sale.

010

Reposted by UCL Business

UCL Engineering @uclengineering.bsky.social · 15/07/2025

One year ago today, we kicked off the UCL Festival of Engineering. Over the next 6 days, we welcomed more than 7000 people to over 250 events across 6 London boroughs. Find out more about what we got up to during a pretty extraordinary week ⬇️

ucl.ac.uk

Six days to save the world: 7,000 people attend UCL Festival of Engineering

The UCL Festival of Engineering, which took place from 15-20 July, brought cutting edge science and engineering to adults and young people from across London and beyond. Here’s the story of the week…

042

Reposted by UCL Business

The Next Leap @thenextleap.is · 31/07/2025

Steven Schooling, who has been managing director of @uclb.bsky.social since 2006, is leaving the TTO today. His achievements include work on the UCL Technology Funds and the upcoming London Atrium, rumoured to be seeking as much as £500 million. thenextleap.is/news/steven-...

thenextleap.is

The Next Leap » UCL Business managing director Steven Schooling steps down

Steven Schooling, who has been with University College London's commercialisation subsidiary since 2006, is leaving today.

011

UCL Business @uclb.bsky.social · 01/08/2025

‘The Bartlett Invents!’ Pitch and Awards event took place this week at IDEALondon where Bartlett staff, PhD students, and researchers showcased the commercialisation potential of their innovative ideas and UCL research. Find out more here: www.uclb.com/2025/08/01/t...

uclb.com

‘The Bartlett Invents!’ Pitch and Awards 2025

‘The Bartlett Invents!’ Pitch and Awards participants pitched their transformative ideas on 29 July to an audience of academics and innovation professionals.

000

Reposted by UCL Business

UCL Faculty of Brain Sciences @uclbrainscience.bsky.social · 22/07/2025

Today is #WorldBrainDay, a global campaign promoting brain health for all ages. At UCL, we're spotlighting some of the groundbreaking research that's shaping the future of brain health and wellbeing. 🧵

1115

UCL Business @uclb.bsky.social · 22/07/2025

Today is World Brain Day 🧠 Take a look back at UCLB’s Neuroscience Symposium article here, where you can read about the neuroscience spinouts that are reshaping the future of brain health and technology: www.uclb.com/2025/06/13/h...

uclb.com

How UCLB’s neuroscience spinouts are changing lives and making breakthroughs

As UCL’s renowned Neuroscience Symposium kicks off, UCLB uncovers its spinouts’ work in this area, from tackling motor neurone disease to redefining artificial intelligence.

010

UCL Business @uclb.bsky.social · 18/07/2025

Last month, UCLB wrapped up the IO Inspire Spring Programme at UCL’s BaseKX incubator, where the event brought together the latest cohort of academic entrepreneurs supported by UCLB’s Ideas to Opportunities (IO) programme. Watch the full video here: vimeo.com/1102472893

vimeo.com

IO Inspire Spring Cohort 2025

This is "IO Inspire Spring Cohort 2025" by UCLB on Vimeo, the home for high quality videos and the people who love them.

010

UCL Business @uclb.bsky.social · 16/07/2025

Don't miss out on the event "The Future is Now – AI in Biotechnology" at Venture Café London this Thursday 17 July. Mark Fisher, Associate Director at UCLB will be on the panel as the event explores cutting-edge models, automation plus much more! Details here: venturecafelondon.org/event/thursd...

venturecafelondon.org

The Future is Now - AI in Biotech - Venture Café London

📍Fora, The Jellicoe, King’s Cross Biology is becoming programmable — are you ready to build with it? The Future is Now – AI in Biotechnology brings together the builders, researchers, and investors dr...

241

UCL Business @uclb.bsky.social · 08/07/2025

Last week was Research Appreciation Day, a day to celebrate the hard work of health researchers and scientists around the world. Take a look at some of the incredible academic research stemming from UCL and UCLB here: vimeo.com/509778597?p=1l

vimeo.com

About UCLB

This is "About UCLB" by UCLB on Vimeo, the home for high quality videos and the people who love them.

000

UCL Business @uclb.bsky.social · 07/07/2025

Congratulations to EnAcuity, a joint spin-out from UCL and Imperial College London, which has been awarded an Innovate UK Smart Grant, with the funding supporting the development of the first-ever software-only surgical hyperspectral imaging solution in the UK. More: www.uclb.com/2025/07/02/e...

uclb.com

EnAcuity awarded Innovate UK Smart Grant for groundbreaking surgical imaging software

EnAcuity, a joint spin-out from UCL and Imperial College London, has been awarded a prestigious Innovate UK Smart Grant worth £300,840. This funding will support the development of the first-ever soft...

020

UCL Business @uclb.bsky.social · 04/07/2025

The NHS’s newly launched 10-Year Health Plan, Fit for the Future, sets out a bold transformation of England’s healthcare system, with many innovative UCLB spinouts already helping to make this vision a reality. Read more here: www.uclb.com/2025/07/04/t...

uclb.com

The UCL spinouts can help power the NHS’s 10-Year Vision

The NHS’s newly launched 10-Year Health Plan, Fit for the Future, sets out a bold transformation of England’s healthcare system. Many innovative UCLB spinouts are already helping make this vision a re...

020

UCL Business @uclb.bsky.social · 03/07/2025

Thank you to those who joined us yesterday for another great IO Converse session, hosted by UCLB Senior Business Manager Dr. Caitriona O'Rourke. We were so pleased to be joined by Dr. Tomas Baldwin, CEO & Co-Founder of UCL spinout Guilford Street Laboratories (GSL).

010

UCL Business @uclb.bsky.social · 02/07/2025

Don't forget to take a look at our newsletter 𝙐𝘾𝙇𝘽 𝙄𝙢𝙥𝙖𝙘𝙩 𝙄𝙣𝙨𝙞𝙜𝙝𝙩𝙨 - a monthly roundup featuring the inspiring stories of success to emerge from commercialising UCL’s world class research. Read June’s UCLB Impact Insights here: www.linkedin.com/newsletters/...

010

Reposted by UCL Business

UCL Innovation and Enterprise @uclenterprise.bsky.social · 01/07/2025

Throughout June UCL staff and doctoral students attended Transform: Creating impact through knowledge exchange, a series of events and workshops designed to help them transform their research and knowledge into real world impact. Read more: bit.ly/3ZVNUNf #UCLTransform

0139

UCL Business @uclb.bsky.social · 26/06/2025

Thanks to all who attended yesterday’s webinar 'Commercialising your research: a guide for clinicians bringing innovation to the market' with Mark Fisher. Mark got in front of the camera to provide some “top tips” for clinicians looking to commercialise their research. Watch: vimeo.com/1096665118

vimeo.com

Mark Fisher - 'Commercialising your research: a guide for clinicians bringing innovation to the market'

This is "Mark Fisher - 'Commercialising your research: a guide for clinicians bringing innovation to the market'" by UCLB on Vimeo, the home…

020